bioAffinity Technologies (NASDAQ:BIAF) reported quarterly losses of $(0.16) per share which met the analyst consensus estimate. This is a 23.81 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $1.85 million which missed the analyst consensus estimate of $2.11 million by 12.09 percent. This is a 22.96 percent decrease over sales of $2.41 million the same period last year.